Biogen | BIIB - Interest Expense On Debt


Biogen reported $72.6M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 4.65M 1.35M Dec/2024
Amgen USD 685M 9M Sep/2025
Bayer EUR 762M 267M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
Incyte USD 592K 2K Sep/2025
Merck USD 327M 22M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pfizer USD 652M 2M Sep/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sanofi EUR -25M 252M Dec/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
United Therapeutics USD 3M 4.3M Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025